The new Access OV Monitor aids in the management of ovarian cancer and is designed for the quantitative determination of cancer antigen 125 (CA 125) levels in human serum and plasma. CA 125 antigen levels are most consistently elevated in patients with ovarian cancer. Monitoring CA 125 levels can enable physicians to evaluate disease progression and response to therapy in patients with ovarian carcinoma.
     Access OV Monitor produces first results in 20 minutes and uses 25 mL of sample for each test. Total imprecision is less than 10 percent over the range of the assay, while calibration stability is up to 28 days. Its liquid calibrators are ready to use and stable from 2ºC to 10°C until expiration date. Access OV Monitor should be used with other clinical methods such as transvaginal ultrasonography and a mathematical algorithm that analyzes rates of change of CA 125.
     Healthy females tested with Access OV Monitor yielded an upper reference limit (97.5 percent) of 35 U/mL. The assay has a dynamic range from 0.5 to 5,000 U/mL, minimal response to known interferences and no “hook” effect up to 120,000 U/mL.
     The test is available on the Access, Access 2 and UniCel DxI 800 immunoassay systems, as well as the Synchron LXi 725 clinical system, which combines chemistry and immunoassay analysis technology with data management and automated sample handling.
Beckman Coulter
www.CLPmag.com
Keywords: disease management, cancer